- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00555971
Therapeutic Utility of Xolair in Patients Undergoing Aspirin Desensitization
A Placebo Controlled, Double-Blind Investigation of the Therapeutic Utility of Xolair (Omalizumab) for Attenuating Aspirin Induced Bronchospasm in Patients With Aspirin Exacerbated Respiratory Disease (AERD) Undergoing Aspirin Desentization
This is a 24 week double-blind study in which subjects will be randomized 2:1 to receive Xolair (Omalizumab) or placebo. 14 subjects will receive Xolair and 7 will receive placebo. Xolair injections will occur every 2-4 weeks. Aspirin desensitization will occur several weeks later. One month after desensitization, the final visit will occur in the GCRC.
We hypothesize that administration of Xolair, a monoclonal anti-IgE antibody, prior to the aspirin desensitization will reduce severity of aspirin-induced reaction.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a 24 week double-blind study consisting of up to 11 office visits for people 18 years of age with aspirin exacerbated respiratory disease (AERD). 21 subjects will participate and will be randomized 2:1 to receive Xolair (Omalizumab) or placebo. 14 subjects will receive Xolair and 7 will receive placebo. Xolair is a FDA approved medication for the treatment of moderate to severe allergic asthma. Injections will occur every 2-4 weeks, for 16 weeks. The dosage will be based upon IgE and body weight. Aspirin desensitization will occur 1-3 weeks later. One month after desensitization, the final visit will occur in the GCRC.
Properly selected patients with aspirin exacerbated respiratory disease (AERD) experience benefit in the course of their disease with aspirin desensitization treatment; however, AERD patients are at risk for potentially serious asthmatic reaction when undergoing aspirin desensitization. For this reason, this procedure is currently performed in a monitored setting. We hypothesize that administration of Xolair, a monoclonal anti-IgE antibody, prior to the aspirin desensitization will reduce severity of aspirin-induced respiratory reaction, and that ultimately, use of Xolair will permit this procedure to be performed safely in outpatient settings. This protocol also entails obtaining blood and urine samples to assess the influence of Xolair, compared with placebo. As aspirin induced reaction occurs via heightened release of leukotrienes combined with greater end organ responsiveness to these mediators, we also will be quantifying the impact of prior administration of Xolair, compared with placebo, on the elevation of urinary LTE4 in association with aspirin challenge and with aspirin provoked reaction.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- The Cleveland Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age > 18 years.
- Fulfill diagnostic criteria for AERD (described below), and be a candidate for aspirin desensitization chronic asthma - frequently moderate-severe or severe patients will have history compatible with variable airflow obstruction. chronic rhinosinusitis - usually requiring previous sinus surgery procedure(s). sinusitis will have been confirmed by imaging studies presently and/or in the past.
history of adverse reaction to aspirin and/or aspirin-like drugs (e.g., ibuprofen, naproxen, etc.) compatible with AERD.
• Candidate for Xolair [Omalizumab] Moderate-severe persistent asthma IgE = 30-700 IU/ml IgE mediated (allergic) potential to inhalant allergen(s) by cutaneous or in vitro testing.
Exclusion Criteria:
- Women of childbearing potential not using appropriate contraception method(s)
- Women currently breastfeeding
- Women who desire to become pregnant during the time of participation in this study
- Men who desire to get someone pregnant during participation in this study
- Known sensitivity to Xolair [Omalizumab].
- IgE level < 30 IU/ml, or > 700 IU/ml.
- No evidence of atopy by immediate hypersensitivity skin testing
- Use of any other investigational agent in the last 30 days
- Age < 18 years.
- Current tobacco habituation.
- Presence of emphysema
- Ethanolism or drug abuse within last 12 months.
- Presence of significant medical condition including malignancy, neurologic, kidney, gastrointestinal, liver or cardiovascular disease
- extensive travel commitments during the study that would interfere with study measurements or clinic visits.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo Group
Subjects randomized to placebo
|
Subjects randomized to Placebo prior to aspirin desensitization
|
Active Comparator: Omalizumab Group
Subjects randomized to omalizumab
|
Subjects randomized to Omalizumab prior to aspirin desensitization
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Without Respiratory Reaction During Aspirin Desensitization
Time Frame: 24 weeks
|
Lack of Respiratory reaction during aspirin desensitization, including Spirometry (FEV1) testing, to assess the efficacy of Xolair on attenuating aspirin induced bronchospasm in patients with AERD.
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurements of Urinary LTE4 in Association With Respiratory Reaction During Aspirin Desensitization
Time Frame: Approximately 24 weeks
|
Measurements of urinary LTE4 in association with aspirin desensitization, comparing subjects randomized to placebo with subjects randomized to omalizumab, with study drug administered for 16 weeks.
Measurements were compared for respiratory reaction in placebo subjects who exhibited either upper or lower airway reaction and after 100 mg aspirin challenge dose in omalizumab subjects who were non-reactors.
For this analysis, the two omalizumab subjects who had respiratory reaction were not included.
|
Approximately 24 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: David M. Lang, M.D., The Cleveland Clinic, Department of Allergy and Immunology
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB 05-066
- Q3637s (Other Grant/Funding Number: Genentech)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aspirin Sensitivity
-
University of UtahUniversity of Colorado, DenverCompleted
-
The Second Hospital of Shandong UniversityRecruitingSurgery | Aspirin SensitivityChina
-
Lawson Health Research InstituteCompletedAsthma | Aspirin Sensitivity | Chronic Rhinosinusitis | Aspirin Exacerbated Respiratory DiseaseCanada
-
Chulalongkorn UniversityCompletedAspirin Sensitivity | Aspirin-exacerbated Respiratory Disease | NSAID-Induced Anaphylactoid Reaction | Aspirin-Induced Angioedema-Urticaria | Aspirin Allergy | NSAID-Induced Asthma | NSAID-Induced Angioedema-Urticaria | Aspirin-Induced Anaphylactoid ReactionThailand
-
University of PennsylvaniaBayer; National Institutes of Health (NIH)CompletedAspirin Resistance | Pharmacological Aspirin Non-responsiveness
-
Hamilton Health Sciences CorporationCompleted
-
Northwell HealthStaten Island University HospitalCompletedAspirin Resistance
-
Chinese University of Hong KongUnknownAspirin | MicrobiotaHong Kong
-
University of Lausanne HospitalsCompletedAspirin ResistanceSwitzerland
-
Azienda Ospedaliera San Giovanni BattistaUnknown
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States